In contrast, medullary carcinomas with sporadic RET mutations or with wild-type RET were observed with heterogeneous expression of AKT/mTOR pathway molecules, which suggests the need for further elucidation of alternative activation mechanisms [46]. This evidence concerns the gene AKT1 and medullary thyroid gland carcinoma.